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Abstract
Papillary Thyroid Cancer (PTC) is a heterogeneous and complex disease; susceptibility to PTC is influenced by the joint
effects of multiple common, low-penetrance genes, although relatively few have been identified to date. Here we applied a
rigorous combined approach to assess both the individual and epistatic contributions of genetic factors to PTC
susceptibility, based on one of the largest series of thyroid cancer cases described to date. In addition to identifying the
involvement of TSHR variation in classic PTC, our pioneer study of epistasis revealed a significant interaction between
variants in STK17B and PAX8. The interaction was detected by MD-MBR (p = 0.00010) and confirmed by other methods, and
then replicated in a second independent series of patients (MD-MBR p = 0.017). Furthermore, we demonstrated an inverse
correlation between expression of PAX8 and STK17B in a set of cell lines derived from human thyroid carcinomas. Overall,
our work sheds additional light on the genetic basis of thyroid cancer susceptibility, and suggests a new direction for the
exploration of the inherited genetic contribution to disease using association studies.
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Introduction
Follicular-cell-derived thyroid carcinomas are the most common
endocrine malignancies and their incidence has remarkably
increased in recent years [1,2]. Among them, papillary thyroid
carcinoma (PTC, 80–85% of cases), and follicular thyroid
carcinoma (FTC, 5–10%) are the most frequent subtypes [3]. It
is widely accepted that follicular-cell-derived thyroid cancer
behaves as a complex disease, where multiple genetic variants,
located on low-penetrance genes (LPG), interact with each other
and with the environment, thus modulating individual suscepti-
bility [4–6].
We previously reported the association of the FOXE1 gene with
PTC susceptibility [7], a result that has been extensively replicated
[8–10]. Until now, most association studies have focused on main
effects and identified only single, or a very limited number of,
genes involved in PTC pathogenesis. Variants in these genes
explain a relatively small proportion of cases. While additional
low-penetrance genes may be identified by future studies of main
effects, it is also likely that common variants at different loci
interact to modify susceptibility. When genetic variants affect the
phenotype jointly in a non-additive way, this gene-gene interaction
is known as epistasis. The detection of epistatic interactions
represents not only statistical, but also computational challenges
[11,12]. These can be overcome by focusing association studies on
genes that a priori could play a role together, either because they
are located on the same pathways, or because they are
differentially expressed in thyroid tumors. The relative risk of
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thyroid cancer for first degree relatives of probands is higher than
that for any other non-Mendelian neoplasia [13–15], suggesting a
stronger genetic component to its etiology and therefore a possibly
higher likelihood of identifying gene-gene interactions.
The aim of this study was to obtain a more comprehensive view
of the genetic basis of PTC by, on the one hand further assessing
the implication of common variants in candidate genes, and on the
other testing for epistatic two-way interactions between these
variants. To this end, a two-step association approach was
adopted, based on one of the largest differentiated thyroid cancer
patient series described so far. It included a discovery set of 609
cases and 525 controls (series I), and two independent replication
series, comprising 969 cases and 1040 controls (series II and III).
We identified and replicated an interaction between variants in
PAX8 and STK17B, suggesting they may be new players in thyroid
cancer susceptibility. Functional assays confirmed that the
expression of these genes is inversely correlated, although the
underlying mechanism leading to the development of cancer has
still to be elucidated.
Results
Expanded Replication Series Further Confirm the
Involvement of FOXE1 in PTC Susceptibility
We further independently replicated the previously reported
association with common variation in the FOXE1 gene [7]. In our
second, more recently collected Spanish case-control series (series
III), comprising 451 PTC cases and 540 controls, we confirmed
the highly significant association for functional variant rs1867277
in the FOXE1 promoter region, under the same multiplicative
model, with an OR (per allele) of 1.44 (95%CI = 1.19–1.74;
P= 2.061024). Overall, based on a combined total of 1358 PTC
cases and 1551 controls of white European origin from Spain and
Italy, a per-allele OR of 1.45 was estimated (95%CI = 1.30–1.61;
P = 4.7610212).
Stratification of Patients Unveils Putative Subtype-
specific Associations between Individual SNPs and
Thyroid Cancer Risk
After genotyping cases and controls in the discovery stage, we
selected 9 variants located on 9 different genes for inclusion in the
replication stage. Each SNP was either the most significant
tagSNP at a given locus, or was consistently predicted to be
functional, as shown in Table 1.
The most significant association in the discovery stage was
obtained for SNP rs2284734 in the TSHR gene (recessive
OR = 2.64; 95% CI = 1.69–4.13; P= 1.861025), suggesting its
involvement as a risk factor specific to the development of classic
PTC. We also observed evidence of a subtype-specific effect for
rs2687834 in the TG gene (recessive OR = 2.28; 95% CI = 1.50–
3.46; P= 1.161024), further suggesting that tumor stratification
appears to be a relevant aspect to consider in association studies.
This is shown graphically in Figure S1. The association of TSHR-
rs2284734 with cPTC was marginally statistically significant in the
replication stage (recessive OR = 1.42; P= 0.058, Table 1). The
associations for remaining 8 SNPs were not replicated.
Epistatic Interaction between STK17B and PAX8 in
Thyroid Cancer Susceptibility
Among all PTC cases, one interaction was consistently observed
in analyses by three methods; epistasis between the SNP-pair
rs721992 and rs6554198, located in the CCDC6 and KIT genes
respectively, was detected by MDR, SNPHarvester and MB-MDR
(Table 2). However, this interaction was not replicated in series II
and III (p = 0.13).
When only considering patients diagnosed with cPTC, one
interaction was detected by four out of the five methods applied.
This interaction, involving SNPs rs4848323 and rs1378624,
located in the PAX8 and STK17B genes, respectively, had an
associated p-value by MB-MDR of 0.00010 in the discovery stage
and of 0.017 in the replication phase (Table 3, Figure 1). The
corresponding p-value from the combined analysis of data from
both stages was 0.00002, estimated by 100,000 permutations. This
interaction was consistently observed by MB-MDR when the
entire PTC case-series (including all subtypes) was considered (p-
value = 0.026 and 0.045 for the discovery and replication stages,
respectively).
In order to gain functional insights into the PAX8-STK17B
interaction, we first assessed the expression of these genes using
data from a previous array-based study of 63 thyroid tumors [16]
and observed an inverse correlation (r =20.77; p = 8.65610214;
Figure S2). We subsequently observed a consistent result in a series
of thyroid cancer cell lines from different human tumors; high
STK17B expression was observed in the most undifferentiated
human anaplastic thyroid cells (8505c, Hth7 and Hth83), which
are characterized by very low or null PAX8 levels (Figure 2).
To explore the relationship between PAX8 and STK17B in
thyroid cancer, rat thyroid cells were Pax8-silenced and the
STK17B expression analyzed. After one day of transient silencing
of PAX8, mRNA levels of PAX8 decreased by approximately 70%
relative to the wild type or the siScamble transfected cells.
However, no change was observed in the mRNA levels of
STK17B. Pax8 protein levels were also lower in the silenced cells
while STK17b levels remained unchanged relative to the
siScamble transfected cells (Fig. 3A). To determine whether the
absence of a correlation was due to the short-term nature of the
silencing, a siPax8-stable cell line was generated and the protein
levels assayed 7, 14 and 21 days after transfection. Again, a
decrease in PAX8 levels was found without a substantial variation
in STK17B levels. (Fig. 3B).
Discussion
Although the number of identified LPGs for follicular-cell-
derived thyroid carcinoma has increased in recent years, it still lags
behind that for other complex diseases. As recently reviewed,
associations have been consistently replicated for only a limited
number of loci [4,6], thus a large proportion of the heritability of
this multifactorial disease remains unexplained.
Thyroid cancer has a strong genetic component, with the
relative risk for first-degree relatives of probands being the highest
among neoplasias not displaying regular Mendelian inheritance
[13–15]. A focus on the identification of new genes through the
assessment of gene-gene interaction may therefore unveil at least
part of this unexplained genetic component. In recent years, the
large number of susceptibility variants identified for complex
diseases has given rise to the need to perform specific analyses to
evaluate their potential epistatic effects. The importance of these
analyses lies mainly in unveiling how the presence of one genetic
variant influences the effect of another variant [17–19].
Such epistatic analyses, unlike those of genetic main effects,
constitute a computational and statistical challenge. Many
methods have been developed to detect epistasis, but all of them
have limitations and their performance is variable. In addition,
some of these methods are computationally unviable for GWAS
data [20]. Since our study considered only 768 SNPs in genes
chosen on the basis of their a priori putative role in the disease, it
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cases OR (95% CI)b P c
MAF in cont;
cases OR (95% CI)b Pc
rs16973034 (A/G) PRKAR1A intronic,
tagSNP
PTC dominant 0.153; 0.108 0.63 (0.47–0.84) 1.861023 0.138; 0.133 1.00 (0.79–1.26) 0.984
rs2703488 (T/C) KIT intronic,
tagSNP
PTC dominant 0.488; 0.551 1.43 (1.07–1.91) 1.561022 0.476; 0.472 0.93 (0.75–1.16) 0.522
rs4939827 (T/C) SMAD7 intronic,
tagSNP
PTC recessive 0.461; 0.416 0.68 (0.50–0.94) 1.961022 0.438; 0.478 1.32 (1.03–1.68) 0.027
rs2066807 (G/C) STAT2 exonic,
p.Met594Ile
PTC dominant 0.033; 0.054 1.69 (1.06–2.69) 2.661022 0.040; 0.039 0.98 (0.68–1.42) 0.928
rs2284734 (A/G) TSHR intronic,
tagSNP
cPTC recessive 0.290; 0.388 2.64 (1.69–4.13) 1.861025 0.304; 0.317 1.42 (0.99–2.03) 0.058
rs1053266 (G/T) CCDC6 exonic,
p.Pro470Thr
cPTC recessive 0.494; 0.543 1.37 (0.96–1.97) 8.761022 0.471; 0.502 1.24 (0.96–1.60) 0.103
rs2687834 (G/T) TG intronic,
tagSNP
fvPTC recessive 0.447; 0.565 2.28 (1.50–3.46) 1.161024 0.491; 0.477 0.74 (0.46–1.17) 0.195
rs6179 (G/A) GHR exonic, ESE FTC dominant 0.356; 0.232 0.46 (0.27–0.80) 5.461023 0.299; 0.286 0.87 (0.55–1.37) 0.543
rs13099828 (C/G) PPARG intronic,
tagSNP
fvPTC+FTC dominant 0.186; 0.256 1.71 (1.22–2.38) 1.661023 0.168; 0.189 1.01 (0.71–1.46) 0.936
Abbreviations: MAF = minor allele frequency; OR = odds ratio; CI = confidence interval; ESE = Exonic Splicing Enhancers; PTC = Papillary Thyroid Carcinoma; cPTC = classic
PTC; fvPTC = follicular variant of PTC; FTC = Follicular Thyroid Carcinoma. The table is sorted by disease subtype and, within each group, by P-value.
aMajor/minor allele (in controls);
bOR and CI were obtained using homozygotes for the most frequent allele in controls as the reference group;
cP-values are derived from Wald statistics;
dResults adjusted for age and gender;
eResults adjusted for age, gender and country.
doi:10.1371/journal.pone.0074765.t001
Table 2. Gene-gene interaction results for susceptibility to Papillary Thyroid Carcinoma overall.
SNP1 GENE SNP2 GENE MDR SH MECPM MSH MBMDR*
rs721992 CCDC6 rs6554198 KIT ,0.0001
rs11985450 ChGn rs3021526 FOXE1 0.0637
rs2395911 SLC26A4 rs1799977 MLH1 0.0002
rs16945753 MED13 rs2979033 TG 0.0045
rs8069645 STAT3 rs2979040 TG 0.0035
rs10119760 FOXE1 rs2958681 TG 0.0190
rs3111800 KIT rs4607021 ITGB2 0.0010
rs10119760 FOXE1 rs15866 STK17A 0.0084
rs6556301 FGFR4 rs6948512 SHH 0.0085
rs2958681 TG rs7350420 NCOA4 0.0298
rs1044217 STK17A rs2958681 TG 0.0114
rs12667481 SLC26A4 rs6180 GHR NA
rs440555 ITGB2 rs6180 GHR 0.0332
rs16945753 MED13 rs17202345 CCDC6 0.0735
rs1648305 DUOX1 rs3098233 CTHRC1 0.0854
rs2703488 KIT rs6018257 SRC 0.0785
rs17705719 TG rs15997 RAF1 0.1085
SH- SNPHarvester; MSH- MegaSNPHunter; light grey shading indicates interactions selected by each of the algorithms; dark grey shading indicates the interaction
fulfilling the established cutoff (SNP pair selected by at least three methods);
*associated P-value; NA- not available (all genotypes combinations classified as neutral).
doi:10.1371/journal.pone.0074765.t002
Epistatic Interaction in PTC Susceptibility
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e74765
was possible to apply several more complex algorithms derived
from complementary strategies, thus increasing the robustness of
interaction detection.
The use of MB-MDR in the second replication stage implied
several advantages, including the possibility to test the exact
epistatic model identified in the discovery stage, and the ability to
adjust for potential confounders, as well as marginal SNP effects,
the latter to avoid the influence on the results of SNP pairs acting
in purely additive way. Furthermore, a permutation-based p-value
could be readily obtained at a reasonable computational cost. The
fact that we were able to replicate one of the two interactions
detected in the discovery stage is testament to the reliability of our
proposed pipeline.
To date, a multitude of studies performed with yeast models
have identified unequivocal gene-gene interactions [21–24]. On
the contrary, attempts to identify epistatic or other kind of
interactions in human disease susceptibility have only relatively
recently started to yield results [25–29]. Nevertheless, few if any
have been convincingly replicated. The present study has, for the
first time, identified and independently replicated an epistatic
association with cPTC susceptibility of common variants in two
genes. This success is likely due not only to having a reduced list of
candidate genes, but also to the high heritability of thyroid cancer,
as well as the careful clinical characterization of the case series to
identify disease subtypes with minimal error.
Our analysis of epistasis, applied to a case-control study based
on a candidate gene approach [7], has identified an interaction
between PAX8 and STK17B. This and future findings of epistatic
genetic associations could be the first step towards a deeper
biological characterization of thyroid cancer. STK17B encodes
DRAK2, a serine-threonine kinase involved in the regulation of
apoptosis. It was initially selected as a candidate gene to study
based on its differential expression in PTC tumors relative to
normal thyroid tissue [7,16]. PAX8 was chosen because it is a well-
known thyroid transcription factor, related to thyroid differenti-
ation, the regulation of specific genes, and to congenital diseases
[30–33]. Interestingly, a recent study combining a genome-wide
analysis of Pax8 binding sites with gene expression profiles has
defined apoptosis as an important pathway under Pax8 regulation
[34]. Although the functional assays performed by siRNA did not
explain the underlying biological mechanism, gene expression
studies based on both human tumors and cell lines have found an
inverse correlation between PAX8 and STK17B. This latter finding
corroborates the findings from the association study, suggesting
that these two loci indeed interact to influence susceptibility to
cPTC. Thus, it is tempting to speculate that PAX8 might play a
role in the regulation of STK17B expression, pointing to this latter,
relatively unknown gene as a new putative player in thyroid
metabolism.
Finally, our results for individual variants in TSHR and possibly
TG, and the epistatic effect of the SNPs in PAX8 and STK17B, all
apparently stronger for specific disease subtypes, stress the
potential importance of tumor characterisation and stratification
in association studies. The association of tagSNP rs2284734 in
TSHR with risk of cPTC was the second most statistically
significant (OR = 2.64; 95% CI = 1.69–4.13; P= 1.861025), with
consistent results observed in the replication stage (OR = 1.42;
95% CI = 0.99–2.03; P= 0.058). Several studies have suggested an
association between TSHR and susceptibility of developing
autoimmune pathologies of the thyroid gland [35–38], one of
them involving the same tagSNP (rs2284734). An association with
Graves’ disease has also been reported [39]. Few studies have
assessed the association between TSHR and thyroid cancer risk
and those that have, have reported negative results so far [40,41].
However, previous studies have evaluated only a limited number
of exonic TSHR variants. It seems premature to rule out this locus
in thyroid cancer susceptibility. Fine-mapping of the region should
be performed in order to identify a functional variant, possibly
intronic and/or regulatory, to explain our observed association
with cPTC.
In summary, we propose additional genetic factors that may
explain part of the unresolved heritability of thyroid cancer. In
addition to identifying a potential role of TSHR variants in cPTC
risk, we have detected and independently replicated for the first
time an epistatic relationship between the PAX8 and STK17B
genes in thyroid cancer susceptibility. This gene-gene interaction
demonstrates that epistatic effects may play an important role on
thyroid cancer, and could explain the lack of an observed
association for each gene individually. Further studies are needed
to determine whether gene-gene interactions can be useful as risk
Figure 1. Epistatic model for SNPs in PAX8 and STK17B and genotype frequencies for cPTC-cases and controls. Relative frequencies of
the nine genotype combinations of the replicated interaction (PAX8-STK17B) are shown for cases and controls (red and blue columns, respectively).
The cell containing the high-risk genotype combination is highlighted in light red, those with low-risk combinations in light blue, and those with
neutral combinations are uncoloured. Figure1a - based on the discovery stage (series I); Figure 1b - based on the replication stage (series II and III);
Figure 1c – based on both stages combined (series I, II and III).
doi:10.1371/journal.pone.0074765.g001
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Written informed consent was obtained from all participants in
accordance protocols approved by the ‘‘Comite´ de bioe´tica y
bienestar animal del Instituto de Salud Carlos III’’ and the Ethics
Committee of the COR (Regional Cancer Center), Padova, Italy,
which approved this study.
Subjects
Three series of thyroid cancer cases and controls were recruited,
as described below:
Discovery (series I). We recruited 609 thyroid cancer
patients from the Spanish hospital network. These included the
main thyroid follicular-cell derived carcinomas: 520 PTC, repre-
sented by the main subtypes ‘classic PTC’ (cPTC; n = 304) and
‘follicular variant PTC’ (fvPTC; n = 146); and 69 follicular thyroid
carcinomas (FTC). Medullary thyroid carcinomas (MTC) were not
included in the study.
A series of 525 cancer-free controls were recruited from the
same geographical regions covered by the hospitals involved in the
study. For both case and controls the mean age was 46 years and
the female:male sex ratio was 4.6:1.
Replication (series II and III combined). A second case-
control series (series II) comprised 412 PTC and 44 FTC patients
recruited at three hospitals located in Italy and 500 controls from
the same three geographical regions.
Table 3. Gene-gene interaction results for susceptibility to classic Papillary Thyroid Carcinoma.
SNP1 GENE SNP2 GENE MDR SH MECPM MSH MBMDR*
rs4848323 PAX8 rs1378624 STK17B ,0.0001
rs3758249 FOXE1 rs1017141 TSHR NA
rs1465618 THADA rs1041457 ITGB2 0.0003
rs2979040 TG rs9912773 STAT3 0.0005
rs10755938 TG rs1706804 DUOX1 0.0632
rs2229642 ITPR3 rs4128209 THADA 0.0005
rs16945753 MED13 rs4682845 PTHR1 0.0027
rs10974947 JAK2 rs1051340 TRIP11 0.0045
rs12691874 CXCR4 rs4128209 THADA 0.0482
rs12941827 MED13 rs2411256 FGFR1 0.0011
rs3763743 CCDC6 rs2025488 CGA 0.0858
rs11985450 ChGn rs4927632 TPO 0.0789
rs17786733 TPO rs2017472 KIT 0.0016
rs1998008 TSHB rs6018257 SRC 0.0409
rs11972418 SLC26A4 rs901854 ITPR1 0.0024
rs2284735 TSHR rs27438 CSF2 0.0052
rs1568400 THRA rs2298566 SNX19 0.0033
rs180202 TG rs10940495 IL6ST 0.0974
rs2701684 SLC26A4 rs6948512 SHH 0.0083
rs1466018 PAX8 rs6554198 KIT 0.0232
rs7559891 THADA rs881301 FGFR1 0.0234
rs1799977 MLH1 rs7048394 FOXE1 0.0033
rs1624715 CCDC6 rs12949918 STAT3 0.0198
rs26279 MSH3 rs920964 CCDC6 NA
rs10146516 TSHR rs2464196 TCF1 0.049
rs11030043 RHOG rs2838738 ITGB2 0.0006
rs11903287 THADA rs7581626 STK17B NA
rs172310 SHH rs6018257 SRC NA
rs2734871 CXCR4 rs16945753 MED13 0.0284
rs2395911 SLC26A4 rs310247 JAK1 NS
rs1799977 MLH1 rs17413525 THADA 0.0017
rs11535853 TG rs4939827 SMAD7 0.0772
rs2235978 TRIP11 rs6873545 GHR 0.0551
SH- SNPHarvester; MSH- MegaSNPHunter; Light grey shading indicates interactions selected by each of the algorithms; dark grey green shading indicates the interaction
fulfilling the established criteria to pass to stage 2 (replication) (SNP pair selected by at least three methods);
*associated P-value; NA- not available (all genotypes combinations classified as neutral).
doi:10.1371/journal.pone.0074765.t003
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A third, independent group of Spanish thyroid cancer patients
were obtained, including 451 PTC and 62 FTC, as well as a
complementary set of 540 Spanish controls (series III).
Overall, the replication study comprised 969 thyroid cancer
cases of white European ancestry, including 863 PTC (582 cPTC
and 118 fvPTC ) and 106 FTC. Their mean age was 47 years and
the female:male sex ratio was 4.4:1. The mean age of the total
1040 controls was 53 years and the female:male sex ratio was
2.4:1.
Clinicians from all participating centers completed a detailed
clinical questionnaire for each patient that included personal and
clinical information, such as tumor subtype and stage, as well as
details of surgery, treatment and the development of metastasis
during follow-up.
DNA Isolation and Quantification
Blood or saliva samples were obtained from all cases and
controls. Genomic DNA was extracted from peripheral blood
lymphocytes by automated methods according to the manufac-
turer’s instructions (Magnapure, Roche, Madrid, Spain), or
manually, using standard methods [42]. DNA was extracted from
saliva using the Oragene DNA Self-Collection Kit (DNA Genotek,
Ottawa, Canada). DNA concentration was quantified in all
samples prior to genotyping using the Quant-iT PicoGreen
dsDNA Reagent (Invitrogen, Eugene, OR, USA).
Gene and SNP Selection
Ninety-seven candidate genes were selected in a biologically
oriented manner and 768 single nucleotide polymorphisms (SNPs)
(Table S1) were identified therein, as previously described [7].
SNP Genotyping
SNPs were genotyped in the discovery stage using the Illumina
GoldenGateH Genotyping Assay (San Diego, CA, USA) system,
on a Sentrix Universal-96 Array Matrix multi-sample array
format. Genotyping for the replication stage was carried out using
the KASPar SNP Genotyping System (Kbiosciences, Herts, UK)
as previously described [7].
Statistical Analysis
Departure from Hardy-Weinberg equilibrium (HWE) for all
SNPs was tested in controls using Fisher’s exact test. SNP main
effects were assessed by estimating genotype-specific odds ratios
(OR) via unconditional logistic regression, using homozygotes of
the most frequent allele in controls as the reference group. For
each SNP, the best fitting genetic model was determined, and the
corresponding p-value was calculated based on the Wald statistic.
All models were adjusted for the putative confounding factors age,
gender, and when relevant, country. We assessed heterogeneity in
the per-allele OR by thyroid cancer subtype using a likelihood-
ratio test, as previously described [43]. Statistical analyses were
performed using SPSS for Windows 17.0 and STATA version
10H, unless otherwise stated.
Methods to Assess SNP-SNP Interactions
We tested for epistasis using cases from homogeneous and
robustly represented disease groups, including PTC overall and
cPTC. We assessed two-way interactions between SNPs using five
different methods, Multifactor Dimensionality Reduction (MDR)
[44,45], Maximum Entropy Conditional Probability Modeling
(MECPM) [46], SNPHarvester [47], MegaSNPHunter [48], and
Model Based - Multifactor Dimensionality Reduction (MB-MDR)
[49]; see Methods S1). We adjusted for sex and age in the
discovery stage, where permitted by the method in question. Only
interactions (SNP pairs) identified by at least three methods were
selected for replication in series II and III. We used MB-MDR to
test in the replication stage the epistatic model identified in the
discovery stage (see Methods S1). Age, sex and country were
included as covariates. MB-MDR assigns each of the nine possible
combined two-SNP genotypes to three risk categories (high, low,
and neutral) using logistic regression. We included age, sex and
country as covariates and computed p-values based on a
permutation test [44,45]. Replication of interactions was assessed
by forcing the genotype combinations into the risk categories
determined in the discovery stage. Interactions with an associated
p-value ,0.05 were considered replicated. A similar strategy was
applied to combined data from both stages for replicated
interactions.
Figure 2. STK17B and PAX8 mRNA levels in thyroid tumoral cell lines. The mRNA expression levels of both genes were determined by qRT-
PCR and are represented as relative units. The name of the cell line and its origin (follicular, papillary or anaplastic) is indicated.
doi:10.1371/journal.pone.0074765.g002
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Functional Assays
Cell culture. Cell lines were kindly donated by Dr. Heldin
(SW1736, Hth7 and Hth83 [50]), Dr. Fagin (WRO [51]) and Dr.
Fusco and Dr. Santoro (BCPAP [52] and TPC-1 [53]), or
obtained from the German Collection of Microorganism and Cells
Culture (Cal62, 8505c) and the European collection of cell culture
(NthyORI, FTC133). All cell lines were genetically fingerprinted
and verified to be unique and of thyroid origin [54].
PCCl3 cells are a continuous line of rat thyroid follicular cells
that express the thyroid-specific transcription factors Nkx2.1,
Foxe1, and Pax8. They were grown in Coon’s modification of
Ham’s F-12 medium, supplemented with 5% donor calf serum
and a six-hormone mixture [55].
The human cell lines used were derived from normal thyroid
tissue or from follicular, papillary or anaplastic thyroid carcino-
mas. 8505c, WRO and SW1736 cells, as well as NthyORI3.1
control cells were grown in RPMI medium, while FTC133, TPC1,
BCPAP and Cal62 cells were growth in DMEM medium, and
Hth7 and Hth83 cells in MEM medium. All the media were
supplemented with 5% fetal bovine serum.
Generation of PCCl3-Pax8-silenced thyroid cells. The
silencing of Pax8 was performed in PCCl3 cells either transiently
or stably. Transient transfection was carried out using the
DharmaFECT 1 siRNA transfection reagent both for scrambled
and for Pax8 siRNA conditions (Dharmacon, Denver, CO). Stable
short hairpin RNA (shRNA) was obtained by infection with
pGIPZ lentiviral plasmid containing the interfering sequence of
puromycin-resistant Pax8 or its control (scramble) (Open Biosys-
tem, Denver, CO).
Total RNA was obtained from control (wild type) and from
transiently-Pax8-silenced cells (siPax8 or scrambled siRNA) using
the TRIzol reagent (Invitrogen, Carlsbad, CA) following the
manufacturer’s recommended protocol; semiquantitative RT-
PCR was then performed as previously described [56] using
specific primers for Pax8 (forward CAAGGTGGTGGAGAA-
GATTG and reverse GAGGTTGAATGGTTGCTG), STK17B
(forward CCTGAGTTGGCTGAAATG and reverse
TCTGTTGCTGTGGTAATGGG) or bactin (forward
CACTCTTCCAGCCTTCCTT and reverse CTCGTCA-
TACTCCTGCTTGCT).
Validation of Pax8 silencing and STK17B expression was tested
either by RT-PCR or by Western blot using a polyclonal Pax8
mouse antibody (Biopat, Milan, Italy) or a human STK17B
antibody (RD System, Minneapolis, MN), respectively. bactin
levels were used as loading control after immunoblotting with a
specific antibody (Santa Cruz Biotechnology, CA).
Supporting Information
Figure S1 Subtype-specific Manhattan plot representa-
tions of the differences in allelic frequencies between
cases and controls in the discovery series. Upper panel:
classic PTC vs. controls; Lower panel: follicular variant of PTC vs.
controls. Highlighted areas correspond to the variants of TSHR
and TG, specifically associated to each of the mentioned PTC
subtypes, respectively. The inserted table shows the results for the
top two variants in their specific subtypes, as well as the
correspondent P-values derived from the likelihood-ratio test, thus
demonstrating the subtype-specificity of TSHR and TG associa-
tions.
(TIF)
Figure S2 Unsupervised clustering for PAX8 and
STK17B probes in our previously published mRNA
array, including 63 thyroid tumors (Montero-Conde
et al, 2008– ref. 26). A significant inverse correlation is
observed (r =20.77; p = 8.65610214). Abbreviations: PTC = Pa-
pillary Thyroid Carcinoma; FVPTC = follicular variant of PTC;
FTC = Follicular Thyroid Carcinoma; FA = Follicular Adenoma;
PDTC = Poorly Differentiated Thyroid Carcinoma; ATC = Ana-
plastic Thyroid Carcinoma; N = Normal Thyroid.
(TIF)
Table S1 Complete list of SNPs studied in the discovery
series.
(DOC)
Methods S1 Brief description of the methods used to
detect epistatic interactions.
(DOC)
Figure 3. Relative expression levels of STK17B in Pax8-silenced
cells. PCCl3 cells were transiently (A) or stably (B) silenced for the
transcription factor Pax8 (siPax8). As a control, wild type or siScramble
transfected cells were used. The expression levels were assessed by
means of qRT-PCR (A, upper panel) or western blot (A, lower panel, and
B).
doi:10.1371/journal.pone.0074765.g003
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